This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • LUX-Head & Neck 1 - A randomised, open-label, phas...
Clinical trial

LUX-Head & Neck 1 - A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have prog

Read time: 1 mins
Last updated:18th Jul 2011
To investigate the efficacy of afatinib versus methotrexate therapy in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based therapy given for R/M HNSCC
Category Value
Study start date 2011-07-18

View full details